Strauss Borrelli PLLC, a leading data breach law firm, is investigating Revance Therapeutics, Inc. regarding its recent data breach. The Revance data breach involved sensitive personal identifiable information belonging to an undetermined number of individuals.
ABOUT LE VIAN CORP.:
Revance is a biotechnology company that focuses on the development, acquisition, and commercialization of pharmaceutical products. Founded in 2002, Revance has two primary divisions: aesthetics and therapeutics. With brands including Daxxify and RHA, Revance’s aesthetics division specializes in injectable facial filling products and provider training. In the therapeutics division, Revance seeks to develop treatments for muscular conditions including cervical dystonia, upper limb spasticity, and plantar fasciitis through product development and clinical trials. Between these two divisions, Revance employs about 500 individuals. In 2021, Revance generated $78 million in revenue.
WHAT HAPPENED?
On April 9, 2023, Revance discovered that it had experienced a data breach in which the sensitive personal identifiable information in its systems may have been accessed and obtained. Through its investigation, Revance determined that an unauthorized actor may have accessed and obtained this sensitive information between March 15, 2023 and April 10, 2023. Recently, Revance began contacting individuals whose information may have been impacted. The type of information exposed includes:
- Name
- Social Security number
- Driver’s license number
- Financial information
If you received a breach notification letter from Revance:
We would like to speak with you about your rights and potential legal remedies in response to this data breach. Please fill out the form, below, or contact us at 872.263.1100 or sam@straussborrelli.com.
